Under Priority Review status, the FDA accepts Deciphera Pharmaceuticals’ (NASDAQ:DCPH)
marketing application seeking approval to use ripretinib to treat
patients with advanced gastrointestinal stromal tumors (GIST).
The agency’s action date is August 13.
https://seekingalpha.com/news/3541333-fda-accepts-deciphera-application-for-ripretinib-for-gist
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.